Anti Inflammatory Treatment of Hypertension

Phase 2

Completed

• Conditions: Hypertension
• Interventions: Drug: Amlodipine; Drug: Levamlodipine

• Registration Number: NCT04740840
• Lead Sponsor: Affiliated Hospital of North Sichuan Medical College

Brief Summary

To investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension

Detailed Description

A total of 200 inpatients or outpatients in the Department of cardiovascular medicine of the third people's Hospital of Mianyang City from April 2021 to October 2021, who met the diagnostic criteria of ish2020 international hypertension practice guidelines, were selected and randomly divided into control group and experimental group, with 100 cases in each group. The control group was treated with amlodipine and the experimental group was treated with levoamlodipine. The changes of blood pressure and serum inflammatory factors were observed before and after treatment.

Study Timeline

• Study Start: 2010-05-01
• Primary Completion: 2012-04-02
• Study Completion: 2015-05-02
• Status Verified: 2021-02
• Study First Submitted: 2021-02-04
• Study First Submitted QC: 2021-02-04
• Last Update Submitted: 2021-02-04
• Study First Posted: 2021-02-05
• Last Update Posted: 2021-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• ① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral contraceptives, Chinese herbal medicine, etc.; Voluntary participation and signing of informed consent, and can complete all the visit plan.

Exclusion Criteria

• (1) Those who do not want to take blood tests; (2) Left ventricular ejection fraction < 50%, heart rate <50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction (ALT BBB 0 80U/L, CR BBB 1 442mmol/L); Autoimmune diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Amlodipine group	Amlodipine	To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
Levamlodipine group	Levamlodipine	Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate

Primary Outcome Measures

Name	Time	Method
After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group	One month after treatment
the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group	One month after treatment
Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs	One month after treatment